Tositumomab

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="52%" style="text-align:center" |- ! colspan="12" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmac...)
Line 52: Line 52:
! Ibritumomab
! Ibritumomab
|-
|-
 +
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab
Line 57: Line 58:
! Ibritumomab
! Ibritumomab
|-
|-
 +
! Dosage (mg)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab
! Rituximab
! Rituximab
! Ibritumomab
! Ibritumomab
 +
|-
 +
! Metabolism
 +
! Tositumomab
 +
! Ofatumumab
 +
! Rituximab
 +
! Ibritumomab
 +
|}
|}
|}

Revision as of 06:38, 6 December 2010

Pharmacokinetics

Anti-CD20 Monoclonal Antibody Pharmacokinetics
Parameter Tositumomab Ofatumumab Rituximab Ibritumomab
Tmax (hr) Tositumomab Ofatumumab Rituximab Ibritumomab
Cmax (ng/ml) Tositumomab Ofatumumab Rituximab Ibritumomab
Bioavailability (%) Tositumomab Ofatumumab Rituximab Ibritumomab
Protein Binding (%) Tositumomab Ofatumumab Rituximab Ibritumomab
T1/2 (hr) Tositumomab Ofatumumab Rituximab Ibritumomab
AUC (ng/ml/hr) Tositumomab Ofatumumab Rituximab Ibritumomab
Clearance (L/h) Tositumomab Ofatumumab Rituximab Ibritumomab
IC50 (nM) Tositumomab Ofatumumab Rituximab Ibritumomab
Dosage (mg) Tositumomab Ofatumumab Rituximab Ibritumomab
Metabolism Tositumomab Ofatumumab Rituximab Ibritumomab

|}

Proteopedia Page Contributors and Editors (what is this?)

David Canner

Personal tools